Drug Trial Radar · NCT04163562
Oral Immunotherapy for Peanut Allergic Patients
Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 11, 2020
Primary completion
May 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- InnoUp Farma S.L.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients. The overall study design consists of two sequential periods of Part A and Part B. Part A is a dose escalation study in patients from 12 to 65 years old with a history of immediate hypersensitive reaction to peanut protein. Six diferent oral-dose of INP20 will be administered to 6 cohorts of patients once daily for 2 weeks. Part B is a 6-month double-blind, placebo-controlled, randomized and parallel groups study. Patients will be randomized in a 1:1:1 ratio into three (3) different treatment groups, including placebo and the two doses of peanut protein selected from Part A. They will recieve INP20 once daily for 6 months.
Conditions
- Peanut Allergy
Interventions
INP20Drug
Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
PlaceboDrug
Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate, severity, and relationship to treatment of adverse events (AEs) and serious adverse events (SAEs)Time frame: Week 4 and Week 25
- Number of patients experiencing any dose limiting toxicity (DLT)Time frame: Week 2
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Complejo Hospittalario de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.